-
公开(公告)号：US20190091266A1
公开(公告)日：2019-03-28
申请号：US16198811
申请日：2018-11-22
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yair Reisner , Carmit Hillel-Karniel , Chava Rosen , Esther Bachar-Lustig , Elias Shezen
Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.
-
公开(公告)号：US10668109B2
公开(公告)日：2020-06-02
申请号：US15737290
申请日：2016-06-16
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair Reisner , Chava Rosen , Elias Shezen , Irit Milman Krentsis
IPC: A61K35/42 , A61K45/06 , A61K31/015 , A61K35/12 , A61K35/28 , C12N5/071 , A61K9/00 , A61K31/255 , A61K31/675 , A61N5/10
Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.
-
公开(公告)号：US20140356335A1
公开(公告)日：2014-12-04
申请号：US14363814
申请日：2012-12-06
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair Reisner , Elias Shezen , Chava Rosen
IPC: A61K35/54
CPC classification number: A61K35/54 , A61K35/42 , C12N5/0688
Abstract: A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed.
Abstract translation: 公开了一种药物组合物，其包含来自哺乳动物胎儿肺组织的分离的细胞悬液群作为活性成分。 胎儿肺组织处于与选自妊娠约20至约22周的妊娠阶段的人肺器官/组织相对应的发育阶段。 还公开了使用该药物组合物的方法。
-
公开(公告)号：US09833482B2
公开(公告)日：2017-12-05
申请号：US14363814
申请日：2012-12-06
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair Reisner , Elias Shezen , Chava Rosen
CPC classification number: A61K35/54 , A61K35/42 , C12N5/0688
Abstract: A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed.
-
-
-
Search Results
4
records
(took 0.025 seconds)
